|
Thread: The big useless compounds list
-
09-18-2008, 08:43 AM #61
-
09-18-2008, 08:46 AM #62
-
09-18-2008, 09:40 AM #63
- Join Date: May 2007
- Location: New York, United States
- Age: 48
- Posts: 8,520
- Rep Power: 33577
No its definitely in the thyroid but I thought I had read about a small amount found in the adrenals as well in an old study. I just reread the study (posted) and it was a different hormone.
Ludvigsen," J. 1969. Some thyroid and adrenal breed
characteristics and their possible relation to pale
exudative muscles in pigs. In W. Sybesma, P. G. van
der Wal and P. Walstra (Ed.) Recent Points of View
on the Condition and Meat Quality of Pigs for
Slaughter. I. V.O., Zeist, The Netherlands. p. 113.Matt Cahill
www.DrivenSports.com
www.drivensports.co.uk
-
09-18-2008, 12:46 PM #64
-
-
09-19-2008, 07:20 PM #65
-
09-19-2008, 07:56 PM #66
I thought glycerine's ability to draw moisture from membranes made it dangerous to consume if not diluted. Not to mention it tastes pretty awful even after dilution.
In the states, they sell glycerine in the first aid aisle of the local pharmacies, and contains something to the tone of "do not injest". My thoughts are due to the characteristics I've stated above."I've seen that the basic motive for success is the driving force of envy." Ecclesiastes 4:4
anabolic xtreme rep
Bob@anabolicx.com
IFFI
-
09-19-2008, 08:03 PM #67
-
09-19-2008, 09:11 PM #68
-
-
09-19-2008, 09:19 PM #69
-
09-19-2008, 09:26 PM #70
-
09-19-2008, 11:45 PM #71
-
09-20-2008, 09:09 AM #72
Does the spike in serum GABA concentrations cause for an increase in substrates (shift in equilibrium)? The substrates would be capable of crossing the BBB (otherwise GABA would never exist in the brain), where their reaction favors the product side, since no exogeneous GABA can get in there to screw with reaction rates.
Sorry for the Q, I'm not on BB.com so much, and never came across any of the instances where you've mentioned it."I've seen that the basic motive for success is the driving force of envy." Ecclesiastes 4:4
anabolic xtreme rep
Bob@anabolicx.com
IFFI
-
-
09-20-2008, 10:00 AM #73
-
09-20-2008, 10:28 AM #74
-
09-20-2008, 03:12 PM #75
-
09-21-2008, 09:24 PM #76
-
-
09-21-2008, 09:28 PM #77
-
09-21-2008, 10:10 PM #78
-
09-21-2008, 10:20 PM #79
- Join Date: Dec 2005
- Location: Atlanta, Georgia, United States
- Age: 54
- Posts: 4,002
- Rep Power: 15131
Would chromium picolinate be included on this list?
"Giving life support to those who overdosed on an underdose of reality."--DarkPoet
First Order Log and Workout Program:
http://forum.bodybuilding.com/showthread.php?t=108602131
Gaspari Thyrotabs Log:
http://forum.bodybuilding.com/showthread.php?t=107877761
Athletic Edge Nutrition IntrAstack log:
http://forum.bodybuilding.com/showthread.php?t=7399561
-
09-21-2008, 11:03 PM #80
-
-
09-22-2008, 12:47 AM #81
I had forgotten about it. Some mod to add these lines to post #2 pls
Chromium
http://forum.bodybuilding.com/showthread.php?t=621929
-
09-22-2008, 07:23 PM #82
-
09-22-2008, 07:51 PM #83
No.
Read here:
http://forum.bodybuilding.com/showth...t=methyl+ester
-
09-22-2008, 11:15 PM #84
-
-
09-23-2008, 02:53 AM #85
-
09-23-2008, 03:13 AM #86
-
09-23-2008, 04:32 AM #87
-
09-23-2008, 05:45 AM #88
-
-
09-23-2008, 07:45 AM #89
- Join Date: May 2007
- Location: New York, United States
- Age: 48
- Posts: 8,520
- Rep Power: 33577
In this study they found that healthy adults who took Ldopa with a COMT inhibitor had an increase of GH. There arent a lot of studies done using Ldopa and healthy patients, you really need to weed through them.
=============================================
J Neural Transm. 1996;103(6):729-36.Links
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Ker?nen T, Gordin A, Koulu M, Scheinin M, Antila S, Sundberg S, Wikberg T.
Orion Research Center, Orion-Farmos, Espoo, Finland.
We studied the effects of entacapone, a novel inhibitor of the enzyme catechol-O-methyltransferase (COMT), on spontaneous and levodopa (LD) modulated secretion of growth hormone (GH) and prolactin (PRL) in 12 healthy male volunteers. The study had a double-blind, cross-over design with two experimental settings. In the first setting the subjects received a single oral dose of 400 mg of entacapone or matching placebo in a randomized order. In the second setting, a single oral dose of 300 mg of LD and 75 mg of carbidopa was administered concomitantly with either 400 mg of entacapone or matching placebo in a randomized order. Entacapone had no effect on resting levels of GH, but PRL concentrations in plasma were slightly lower after entacapone than after placebo. As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. The effects of LD were not influenced by concomitant administration of entacapone. Compared with the administration of LD/carbidopa together with placebo, concomitant administration of entacapone increased the AUC of LD by 29% and reduced the AUC of 3-O-methyldopa (a metabolite of LD produced by COMT) by 69%. Entacapone appears not to enhance the effects of LD on hypothalamic-pituitary function, although the LD dose used may have been bigger than optimal for detection of a small modulatory influence.
Found another:
Horm Res. 1991;36(1-2):41-6.Links
Dopaminergic regulation of gonadotropin and thyrotropin hormone secretion is altered with age.
Greenspan SL, Sparrow D, Rowe JW.
Division of Gerontology, Beth Israel Hospital, Boston, Mass.
To determine if age-related changes in glycoprotein pituitary hormone secretion are associated with alterations in dopaminergic regulation, plasma gonadotropins and TSH were measured before and after L-dopa administration in 44 young (31-44 years of age) and 42 old (64-88 years of age) healthy male participants. Plasma GH and PRL were also determined in order to examine the ****totroph and lactotrope response. In the young, following L-dopa, plasma FSH, LH and TSH were unchanged from baseline. However, in older subjects, plasma FSH was significantly increased (p less than 0.001) and a similar trend was noted for LH. Plasma TSH was significantly depressed (p less than 0.002) in older subjects only. Following L-dopa, increases in plasma GH and decreases in plasma PRL were of similar magnitude in each group. These data indicate that dopaminergic modulation of gonadotropins and TSH is altered w
Another:
Clin Endocrinol (Oxf). 1984 Nov;21(5):535-40.Links
Inhibitory effect of cimetidine on L-dopa-stimulated growth hormone release in normal man.
Zanoboni A, Galmozzi G, Marinoni S, Zanoboni-Muciaccia W.
Some evidence suggests the existence of a histaminergic influence on GH secretion in animals and man. We used cimetidine, a specific H2-receptor antagonist, to study the possible interference of H2-receptor blockade on plasma GH release by L-dopa and on PRL inhibition by L-dopa in normal man. Seven healthy normal male volunteers aged 23-36 years received a single oral dose of L-dopa (500 mg) or an i.v. bolus of cimetidine (300 mg) or both (L-dopa 30 min before cimetidine). Blood samples were taken at various times over 2 h and plasma GH and PRL levels measured. Cimetidine alone did not alter basal plasma GH values; L-dopa elicited the well-known GH releasing effect with peak values at 75 min (15.65 +/- 2.8 ng/ml); cimetidine injected 30 min after L-dopa ingestion significantly blunted the GH response to L-dopa and peak values (4.7 +/- 1.6 ng/ml) were delayed to 105 min. Cimetidine provoked a rapid rise in plasma PRL with the peak value of 15 +/- 3 ng/ml at 15 min, followed by a return to near basal values in 90-120 min. L-Dopa completely inhibited the PRL response to cimetidine. We conclude that there is an inhibitory influence of the H2-receptor antagonist cimetidine on GH release by L-dopa. This, together with the action of cimetidine on PRL secretion (with or without L-dopa), suggests a possible antidopaminergic effect of H2-receptor blockade at the level of the central nervous system.
Dont take L-Dopa with sugar if you are looking for a GH response:
Diabetes. 1978 Apr;27(4):396-9.Links
Effect of glucose on the glucagon response to L-dopa in normal and diabetic subjects.
Klimes I, Vigas M, Jurcovicov? J, Repcekov? D, Koles?r P.
The effect of an oral dose of 1 gm. L-dopa either without or after a concomitant oral administration of 100 gm. glucose on the plasma level of pancreatic glucagon, plasma immunoreactive insulin (IRI), and plasma growth hormone (GH) was assessed in eight normal and 10 insulin-treated diabetic subjects. In the normal group the stimulatory effect o L-dopa on pancreatic glucagon release was reconfirmed. Moreover, in the diabetics essentially the same plasma glucagon increase after drug administration was found, such a response being inhibited in both groups by glucose. The increase of plasma GH after L-dopa in both healthy persons and diabetics and the inhibition of this response by glucose in healthy subjects was reconfirmed. Furthermore, the same effect of exogenous glucose on the L-dopa induced GH release was observed in diabetics. It may be concluded that glucagon may play a pathogenetic role in the worsening of parkinsonian diabetic patients during the treatment with L-dopa and that diabetic hyperglycemia per se seems to be insufficient for an inhibition of the release of both glucagon and GH AFTer L-dopa.
Last one:
Clin Endocrinol (Oxf). 1975 May;4(3):277-85.Links
Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
Lal S, Martin JB, De la Vega CE, Friesen HG.
Apomorphine hydrochloride (0.75 mg s.c.) has been compared with L-dopa (500 mg p.o.) in their effects on growth hormone secretion in a double blind cross-over study involving nine healthy men. Apomorphine increased serum GH levels above 10 ng/ml in all nine subjects 30-60 min after injection. In contrast, only six of these subjects showed a similar elevation with L-DOPA and in only three had the level increased above 6 ng/ml by 60 min. One subject failed to respond to L-dopa and in two others the peak was less than 6 ng/ml. GH levels were significantly higher at 30, 45 and 60 min following apomorphine than following L-dopa. Apomorphine-induced GH release was not related to changes in serum cortisol or blood sugar. Benztropine mesylate (1 mg i.m.) had no effect on apomorphine-induced GH release. These results suggest: (a) apomorphine may have advantages over L-dopa as a provocative agent to assess GH secretory capacity; (b) a dopaminergic mechanism subserves GH secretion; (c) cholinergic mechanisms do not antagonize dopaminergic-related GH release.Last edited by Sldge; 09-23-2008 at 07:53 AM.
Matt Cahill
www.DrivenSports.com
www.drivensports.co.uk
-
09-23-2008, 07:46 AM #90
Bookmarks